NCT01212341已完成1 期
A Phase I Study of Allogeneic NK Cell Therapy in Patients With Refractory/Relapsed Lymphoma or Solid Tumor
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- To determine the MTD of allogenetic NK cells
研究概览
简要总结
Allogeneic natural killer (NK) cells (MG4101) were manufactured from normal healthy donor who underwent leukapheresis. These cells were processed based on a novel method for ex vivo activation and expansion using an irradiated and activated autologous feeder cell system. MG4101 has anti-tumor activities against various tumors including malignant lymphomas in vitro as well as in vivo tumor model.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older
- •Histologically or cytologically confirmed malignant lymphoma or solid tumor
- •After the failure of standard treatment
- •KPS >70 or ECOG PS 0-2
- •Adequate bone marrow, renal, and liver functions
- •Expected survival at least 3 months
- •Informed consent
排除标准
- •Pregnancy or lactating woman
- •HIV patients
- •Prior exposure to cell-based therapy
- •Hypersensitivity to interleukin-2
- •Patients with autoimmune disease
结局指标
主要结局
To determine the MTD of allogenetic NK cells
时间窗: 4-5 weeks
DLT is defined as follows: * Any toxicity at grade 3 or over for 5 days or more * All grade 4 toxicities * GVHD at grade 2 or over
次要结局
- To evaluate the safety(4 -5 weeks)
- To evaluate the pharmacokinetics of allogeneic NK cells(4-5 weeks)
- To determine the overall response rate(4-5 weeks)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
1 期
Autologous Natural Killer Cell Therapy for Hepatocellular CarcinomaHepatocellular CarcinomaNCT06044506Dr Cipto Mangunkusumo General Hospital3
已完成
1 期
Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid MalignanciesAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Erythroid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia in RemissionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveBlasts Under 20 Percent of Bone Marrow Nucleated CellsBlasts Under 20 Percent of Peripheral Blood White CellsHigh Risk Myelodysplastic SyndromeRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveTherapy-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeMyelodysplastic SyndromeAcute Myeloid LeukemiaChronic Myelomonocytic LeukemiaAcute Megakaryoblastic LeukemiaNCT01823198M.D. Anderson Cancer Center63
已完成
不适用
atural Killer (NK) Cell Therapy Combined with Hepatic Artery Infusion Chemotherapy (HAIC) in Patients with Advanced Hepatocellular CarcinomaNeoplasmsKCT0004642Vaxcell-Bio20
Unknown
1 期
NK Cells in Cord Blood TransplantationAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia in RemissionChronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell MyelomaHigh Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 RearrangementsISS Stage II Plasma Cell MyelomaISS Stage III Plasma Cell MyelomaRecurrent Acute Lymphoblastic LeukemiaRecurrent Acute Myeloid LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Hodgkin LymphomaRecurrent Non-Hodgkin LymphomaRecurrent Small Lymphocytic LymphomaRefractory Acute Lymphoblastic LeukemiaRefractory Chronic Lymphocytic LeukemiaRefractory Hodgkin LymphomaRefractory Non-Hodgkin LymphomaRefractory Small Lymphocytic LymphomaSecondary Acute Myeloid LeukemiaTherapy-Related Acute Myeloid LeukemiaTherapy-Related Myelodysplastic SyndromeMyelodysplastic SyndromeNCT01619761M.D. Anderson Cancer Center13
招募中
1 期
Ex Vivo Expanded NK Cells Infusion Decrease Relapse Post Hematopoietic Stem Cell TransplantationHematologic MalignancyNCT05250362Sichuan University56